FWD1802 + everolimus

FWD1802 + everolimus is an investigational combination therapy under evaluation primarily for the treatment of breast cancer, especially estrogen receptor positive (ER+), HER2 negative advanced or metastatic breast cancer. - **FWD1802** is a monoclonal antibody targeting the macrophage receptor with collagenous structure (MARCO), being developed as a novel immunotherapy to alter tumor-associated macrophage activity and reprogram the tumor microenvironment. - **Everolimus** is a small molecule inhibitor of mammalian target of rapamycin complex 1 (mTORC1), approved for multiple indications including hormone receptor positive breast cancer, renal cell carcinoma, and others. The combination seeks to leverage the immunomodulatory effects of FWD1802 with the antiproliferative, antineoplastic effects of everolimus. Clinical development is ongoing, with the combination being evaluated in early-phase clinical trials in advanced ER+/HER2- breast cancer patients, particularly those resistant to endocrine therapies[1].